fda semaglutide news PRESS The US Food and Drug Administration (FDA) has approved our once-weekly high-dose injectable (7.2 mg) to reduce excess body weight and maintain more weight loss long-term. Learn more in the FDA approves obesity drug that

Published data on semaglutide formulations show measurable degradation begins within hours at room temperature, which is why pharmaceutical standards mandate cold-chain storage for all compounded GLP-1 preparations

Call us at 571-500-7030

Absence of many reports is not proof of low risk BPC-157 use is difficult to measure, products may be sold outside conventional medical channels, and adverse events may never be recognized or reported

Each year, we help thousands of individuals and couples in the Bay Area reach optimal performance, lose weight, feel younger, optimize their workout, and rebalance their hormones